In this background, novel anti-diabetic agents, like dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium–glucose cotransporter-2 inhibitors (SGLT-2i) seem to be particularly attractive due to the low risk of hypoglycaemia and the potential beneficial effects on cardiovascular outcomes reported in large, randomized trials on patients with CAD regardless of diabetes [100]. This evidence concerns the gene GLP1R and coronary artery disorder.